Attilio Orazi: Influence Statistics

Attilio Orazi

Attilio Orazi

Department of Pathology, Texas Tech University Health Sciences Center, El Paso, TX, USA. | Department of Pathology, Texas Tech University Health Sciences Center El Paso, 4800 ...

Attilio Orazi: Expert Impact

Concepts for which Attilio Orazi has direct influence: Bone marrow , Acute myeloid leukemia , Myelodysplastic syndromes , Myeloid leukemia , Primary myelofibrosis , Cell lymphoma , Myeloproliferative neoplasms .

Attilio Orazi: KOL impact

Concepts related to the work of other authors for which for which Attilio Orazi has influence: Bone marrow , Acute myeloid leukemia , Myelodysplastic syndromes , Cell lymphoma , Myeloproliferative neoplasms , Polycythemia vera , Essential thrombocythemia .

KOL Resume for Attilio Orazi

Year
2022

Department of Pathology, Texas Tech University Health Sciences Center, El Paso, TX, USA.

Texas Tech University Health Sciences Center, El Paso, Texas, United States.

2021

Departments of Pathology, Texas Tech University Health Sciences Center, PL Foster School of Medicine, El Paso, TX, USA

Department of Pathology, Texas Tech University Health Sciences Center El Paso, United States of America

2020

Department of Pathology, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas

2019

Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA;

Dept. Pathology and Laboratory Medicine,Weill Cornell Medical College/New York Presbyterian Hospital

2018

Division of Hematopathology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA

Pathology, Weill Cornell Medical College, New York, NY

2017

Department of Pathology and Laboratory Medicine Weill Cornell Medical College/New York Presbyterian Hospital New York New York

2016

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, 1300 York Avenue, 10065, New York, NY, USA

Weill Medical College of Cornell University, New York, New York.

2015

From the Division of Hematopathology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY.

Weill Cornell Medical College, New York, NY;

2014

Weill Medical College of Cornell University, New York, NY

2013

Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital, Weill Cornell Medical Center, New York, NY, USA

Weill Medical College of Cornell University, New York, NY;

2012

Division of Hematopathology, Weill Cornell Medical College, New York, NY

Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York

2011

Hematopathology Division, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, 1300 York Avenue, 10065, New York, NY, USA

Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York

2010

Department of Pathology; Indiana University School of Medicine, Indianapolis, IN; and

Division of Hematopathology, Weill Cornell Medical Center-New York Presbyterian Hospital, New York, NY

2009

Weill Medical College of Cornell University, Department of Pathology and Laboratory Medicine, New York, NY, USA

2008

Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Clarian Pathology Laboratory, Room 5044, 350 West 11th Street, Indianapolis, IN 46202-5200, USA

William Beaumont Hospital, Royal Oak, MI Indiana University School of Medicine, Indianapolis, IN William Beaumont Hospital, Royal Oak, MI Indiana University School of Medicine, Indianapolis, IN William Beaumont Hospital, Royal Oak, MI Indiana University School of Medicine, Indianapolis, IN

Prominent publications by Attilio Orazi

KOL-Index: 17220 . Acute myeloid leukemia arising from chronic myelomonocytic leukemia is currently classified as acute myeloid leukemia with myelodysplasia-related changes, a high-risk subtype. However, the specific features of these cases have not been well described. We studied 38 patients with chronic myelomonocytic leukemia who progressed to acute myeloid leukemia. We compared the clinicopathologic and ...
Known for Myeloid Leukemia | Chronic Myelomonocytic | Myelodysplastic Syndromes | Npm1 Mutation
KOL-Index: 17141 . Double-hit B-cell lymphoma is a common designation for a group of tumors characterized by concurrent translocations of MYC and BCL2, BCL6, or other genes. The prognosis of concurrent MYC and BCL6 translocations is not well known. In this study, we assessed rearrangements and expression of MYC, BCL2 and BCL6 in 898 patients with de novo diffuse large B-cell lymphoma treated with standard ...
Known for Cell Lymphoma | Diffuse Large | Myc Bcl6 | Protooncogene Proteins
KOL-Index: 16425 . Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal center B-cell (GCB)-like and unfavorable activated B-cell (ABC)-like subtypes based on gene expression signatures. In this study, we analyzed 893 de novo DLBCL patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). We show that MYC/BCL2 protein ...
Known for Gene Expression | Inferior Survival | Patients Dlbcl | Cell Subtype
KOL-Index: 16421 . PURPOSE: Approximately 5% of diffuse large B-cell lymphomas (DLBCLs) are double-hit lymphomas (DHLs) with translocations of both MYC and BCL2. DHLs are characterized by poor outcome. We tested whether DLBCLs with high expression of MYC protein and BCL2 protein share the clinical features and poor prognosis of DHLs. PATIENTS AND METHODS: Paraffin-embedded lymphoma samples from 193 patients ...
Known for Lymphoma Treated | Strong Predictor | Doxorubicin Vincristine | Myc Bcl2
KOL-Index: 14913 . Acute myeloid leukemia and myelodysplastic syndrome with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) have a poor prognosis. Indeed, the inv(3)(q21q26.2)/t(3;3)(q21;q26.2) has been recognized as a poor risk karyotype in the revised International Prognostic Scoring System. However, inv(3)(q21q26.2)/t(3;3)(q21;q26.2) is not among the cytogenetic abnormalities pathognomonic for diagnosis of acute ...
Known for Acute Myeloid Leukemia | Myelodysplastic Syndrome | Inv3q21q262 T33q21q262 | Blast Percentage
KOL-Index: 14741 . In spite of the impressive advances in the area of molecular pathology, bone marrow morphology remains the diagnosis cornerstone to identify the various subtypes of myeloid neoplasms. Morphological examination of the bone marrow requires both bone marrow aspirate and bone marrow trephine biopsy. Immunohistochemistry of bone marrow biopsy with markers reactive in paraffin-embedded tissues ...
Known for Myelodysplastic Syndromes | Acute Myeloid | Bone Marrow | Flow Cytometry
KOL-Index: 14416 . Abnormal expression of the chemokine receptor CXCR4 plays an essential role in tumor cell dissemination and disease progression. However, the significance of CXCR4 overexpression in de novo diffuse large B cell lymphoma (DLBCL) is unknown. In 743 patients with de novo diffuse large B cell lymphoma (DLBCL) who received standard Rituximab-CHOP immunochemotherapy, we assessed the expression ...
Known for Cell Lymphoma | Cxcr4 Expression | Diffuse Large | Germinal Center
KOL-Index: 14323 . PURPOSE: Activated signal transducer and activator of transcription 3 (STAT3) regulates tumor growth, invasion, cell proliferation, angiogenesis, immune response, and survival. Data regarding expression of phosphorylated (activated) STAT3 in diffuse large B-cell lymphoma (DLBCL) and the impact of phosphorylated STAT3 (pSTAT3) on prognosis are limited. EXPERIMENTAL DESIGN: We evaluated ...
Known for Stat3 Expression | Cell Lymphoma | Novo Diffuse | Clinical Implications
KOL-Index: 14144 . Diffuse large B-cell lymphoma can be classified by gene expression profiling into germinal center and activated B-cell subtypes with different prognoses after rituximab-CHOP. The importance of previously recognized prognostic markers, such as Bcl-2 protein expression and BCL2 gene abnormalities, has been questioned in the new therapeutic era. We analyzed Bcl-2 protein expression, and BCL2 ...
Known for Germinal Center | Bcl2 Translocations | Poor Outcome | Cell Lymphoma
KOL-Index: 14055 . The World Health Organization criteria for diagnosing chronic myelomonocytic leukemia (CMML) are largely based on findings observed in the peripheral blood and bone marrow aspirate. A specific diagnostic role for the bone marrow biopsy has not been adequately explored. We examined whether bone marrow biopsy supplemented by immunohistochemistry may be helpful in distinguishing CMML from ...
Known for Bone Marrow | Chronic Myelomonocytic Leukemia | Cases Cmml | Tumor Biopsy
KOL-Index: 13991 . Bevacizumab is a humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF-A). Non-Hodgkin's lymphoma patients with high serum VEGF levels have an inferior survival compared to patients with low VEGF levels. Bevacizumab was administered through a central line at 15 mg kg(-1) IV on day 1 followed by rituximab (R) and CHOP on day 2 for cycle 1 and day 1 for ...
Known for Monoclonal Antibodies | Bevacizumab Chop | Diffuse Large | Cell Lymphoma
KOL-Index: 13685 . CD30, originally identified as a cell-surface marker of Reed-Sternberg and Hodgkin cells of classical Hodgkin lymphoma, is also expressed by several types of non-Hodgkin lymphoma, including a subset of diffuse large B-cell lymphoma (DLBCL). However, the prognostic and biological importance of CD30 expression in DLBCL is unknown. Here we report that CD30 expression is a favorable prognostic ...
Known for Cd30 Expression | Diffuse Large | Cell Lymphoma | Favorable Prognosis
KOL-Index: 13307 . Interdigitating dendritic cell sarcoma (IDCS) is a rare tumor derived from interdigitating dendritic cells. Three cases of IDCS associated with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have been described, but no clonal relationship between the 2 neoplasms was demonstrated. We present a detailed case analysis of a CLL/SLL with metachronous IDCS and demonstrate that ...
Known for Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Dendritic Cell | Cll Sll
KOL-Index: 13133 . Chronic myelomonocytic leukemia is characterized by persistent absolute monocytosis (≥1 × 109/l) in the peripheral blood and dysplasia in ≥1 lineages. In the absence of dysplasia, an acquired clonal genetic abnormality is required or causes for reactive monocytosis have to be excluded. Oligomonocytic chronic myelomonocytic leukemia showing increased monocytes but no absolute monocytosis in ...
Known for Chronic Myelomonocytic | Absolute Monocytosis | Peripheral Blood | Myelodysplastic Syndrome
KOL-Index: 12664 . Gene expression profiling (GEP) has stratified diffuse large B-cell lymphoma (DLBCL) into molecular subgroups that correspond to different stages of lymphocyte development–namely germinal center B-cell like and activated B-cell like. This classification has prognostic significance, but GEP is expensive and not readily applicable into daily practice, which has lead to immunohistochemical ...
Known for Gene Expression | Dlbcl Rituximab | Diffuse Large | Cell Lymphoma

Key People For Bone Marrow

Top KOLs in the world
#1
Irving Lerner Weissman
stem cells bone marrow inbred balb mice
#2
Rainer F Rainer
marrow transplantation host disease aplastic anemia
#3
Darwin J Prockop
osteogenesis imperfecta stem cells transgenic mice
#4
E Donnal L Thomas
marrow transplantation host disease aplastic anemia
#5
David T Scadden
bone marrow stem cell multiple myeloma
#6
Mark F Pittenger
stem cells myocardial infarction bone marrow

Department of Pathology, Texas Tech University Health Sciences Center, El Paso, TX, USA. | Department of Pathology, Texas Tech University Health Sciences Center El Paso, 4800 Alberta Avenue, 79905, El Paso, TX, USA | Texas Tech University Health Scie